Dyslipidemia

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.

No difference was observed between atrial shunt placement and sham in the endpoint of CVD death, non-fatal ischemic stroke at 12 months, and rate of total heart failure events at 24 months.

Analysis of real-world registry data presented at ISC 2022 provide insight into the risk of intracranial hemorrhage with tenecteplase versus alteplase in patients with acute ischemic stroke.

Data from an analysis of the ALSPAC cohort suggests arterial stiffness in adolescence could cause insulin resistance and dyslipidemia in young adulthood.

Data show among patients with focal FDG uptake, PET/MRI and inflammatory blood markers resolved at follow-up performed at a mean of 52 days after baseline.

Data show the 1-year incidence of the composite primary endpoint was 10.6% among patients randomized to FFR-guided PCI and 6.9% in CABG.

Sexual activity was involved in 0.2% of all SCDs, with sudden arrhythmic death syndrome and cardiomyopathies predominant underlying causes.

Abbott's device is designed to create highly detailed 3-dimensional maps of the heart to help physicians identify and treat abnormal rhythms.

Data show Black and White patients had a similar risk of MACE over a median 24.4-month follow-up.

From the pooled results of TRILOGY 1 and 2, data show 4 g/d of ω-3–PL/FFA reduced TG levels by 10.9% at 12 weeks and 12.7% at 26 weeks, relative to placebo.

Announced on December 22, the approval of inclisiran (Leqvio) comes nearly a year after the original PDUFA date. With approval, inclisiran becomes the first and only siRNA therapy approved to lower LDL-C with twice-yearly dosing.

Announced on Dec. 20, the latest approvals for rivaroxaban (Xarelto) mark the 10th and 11th indications for the factor Xa inhibitor in the US.

Cardiologists have utilized new technologies during the COVID-19 pandemic.

Data from an analysis of 67k older Danes suggests statin discontinuation corresponded with 1 excess event per 112 persons per year in a primary prevention cohort and 1 excess event per 77 persons per year in a secondary prevention cohort.

The Practical Cardiology editorial staff has compiled a list of 6 noteworthy posters related to cardiology from the Metabolic Institute of America's 19th annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease.

November's cardiology month in review features stories from the AHA's late-breaking sessions and Kidney Week 2021.

Study data show for each $1,000 decrease in median household income, the number of TAVR procedures performed per 100,000 Medicare beneficiaries was 0.2% lower.

The treatment was effective across all weight groups.

The latest data from the digital care transformation program provides insight into effects of digital monitoring programs on helping patients achieve blood pressure and cholesterol goals.

More than 90% of patients in hypertension and lipid management accomplished their predetermined goals after completing the remote program.

Every year, AHA Scientific Sessions provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for late-breaking data from AHA 2021 Scientific Sessions includes AVATAR, RAPID CABG, REVERSE-IT, and more.

Viet Le, PA-C, discusses the results of a study he led from AHA 2021 examining 10-year risk of MACE among patients with an LDL-C from 160-189 mg/dL compared to those with an LDL-C below 160 mg/dL.

Deepak Bhatt, MD, MPH, discusses the results of the interim analysis of the REVERSE-IT trial presented at AHA 2021, which indicates bentracimab provided immediate and sustained reversal of ticagrelor's antiplatelet effects in patients requiring urgent surgery or experiencing major bleeding.

After 2 years, there was little difference in cognitive function between patients with nonvalvular atrial fibrillation receiving dabigatran or warfarin in the GIRAF trial, which was presented at AHA 2021.

Compared to patients who were statin tolerant, patients reporting statin intolerance had more than double the number of listed drug allergies or intolerances to other medications.